FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trial
暂无分享,去创建一个
Jeffrey W. Clark | C. Azzoli | J. Meyerhardt | R. Jain | Y. Boucher | C. Fuchs | P. Enzinger | D. Schrag | D. Rubinson | N. Horick | T. Abrams | M. Yurgelun | D. Duda | K. Ng | L. Goyal | G. Brooks | L. Blaszkowsky | D. Savarese | J. Cleary | N. McCleary | J. Chan | Christopher Graham | Bridget Fitzpatrick | Kathryn A Gibb
[1] C. Hsueh,et al. Targeted and novel therapy in advanced gastric cancer , 2019, Experimental Hematology & Oncology.
[2] Mei-ling Zhu,et al. Prognostic value and association of Lauren classification with VEGF and VEGFR-2 expression in gastric cancer , 2019, Oncology letters.
[3] J. Lacy,et al. RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. , 2018 .
[4] J. Meyerhardt,et al. Patterns of chemotherapy (CT) use in a U.S.-wide cohort of patients (pts) with metastatic gastric cancer (MGC). , 2018 .
[5] P. Philip,et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Quan P. Ly,et al. Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology , 2016 .
[7] A. Benson,et al. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Ying Cheng,et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Roh,et al. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] R. Kelly,et al. State of the art management of metastatic gastroesophageal cancer. , 2015, Annals of translational medicine.
[11] R. Jain,et al. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.
[12] Naotoshi Sugimoto,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[13] K. Kelly,et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Jianming Xu,et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study) , 2014, Gastric Cancer.
[15] J. Berlin,et al. Aflibercept—a Decoy VEGF Receptor , 2014, Current Oncology Reports.
[16] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[17] J. Neal,et al. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer , 2013, British Journal of Cancer.
[18] Thierry Gil,et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.
[19] E. Van Cutsem,et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Shah,et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Loibl,et al. Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis , 2011, BMC Cancer.